PT4181920T - Inibidor de kat6 e combinações para o tratamento do cancro da mama - Google Patents
Inibidor de kat6 e combinações para o tratamento do cancro da mamaInfo
- Publication number
- PT4181920T PT4181920T PT217495506T PT21749550T PT4181920T PT 4181920 T PT4181920 T PT 4181920T PT 217495506 T PT217495506 T PT 217495506T PT 21749550 T PT21749550 T PT 21749550T PT 4181920 T PT4181920 T PT 4181920T
- Authority
- PT
- Portugal
- Prior art keywords
- kat6
- combinations
- cancer treatment
- inhibitor methods
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052215P | 2020-07-15 | 2020-07-15 | |
| US202163211044P | 2021-06-16 | 2021-06-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT4181920T true PT4181920T (pt) | 2025-11-04 |
Family
ID=77179980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT217495506T PT4181920T (pt) | 2020-07-15 | 2021-07-15 | Inibidor de kat6 e combinações para o tratamento do cancro da mama |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP4181920B1 (pt) |
| JP (1) | JP2022019654A (pt) |
| KR (1) | KR20230058614A (pt) |
| CN (1) | CN116113407A (pt) |
| AU (2) | AU2021308406A1 (pt) |
| BR (1) | BR112023000687A2 (pt) |
| CA (1) | CA3189410A1 (pt) |
| DK (1) | DK4181920T3 (pt) |
| FI (1) | FI4181920T3 (pt) |
| IL (1) | IL299871A (pt) |
| MX (1) | MX2023000735A (pt) |
| PT (1) | PT4181920T (pt) |
| TW (1) | TW202216131A (pt) |
| WO (1) | WO2022013369A1 (pt) |
| ZA (1) | ZA202300875B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114072394A (zh) | 2019-04-25 | 2022-02-18 | 拜耳股份公司 | 用于治疗癌症的酰基磺酰胺 |
| US20240400545A1 (en) * | 2021-07-05 | 2024-12-05 | Hangzhou Innogate Pharma Co., Ltd. | Compound serving as kat6 inhibitor |
| EP4433474A4 (en) | 2021-11-16 | 2025-10-22 | Insilico Medicine Ip Ltd | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND THEIR USES |
| EP4440576A1 (en) * | 2021-12-02 | 2024-10-09 | Pfizer Inc. | Cdk4 inhibitor for the treatment of cancer |
| CN116621859A (zh) * | 2022-02-18 | 2023-08-22 | 山东轩竹医药科技有限公司 | 三并环类kat6抑制剂 |
| JP2025511122A (ja) | 2022-03-28 | 2025-04-15 | アイソステリックス， インコーポレイテッド | リジンアセチルトランスフェラーゼのｍｙｓｔファミリーの阻害剤 |
| JP2025533719A (ja) | 2022-07-29 | 2025-10-09 | ファイザー・インク | がんの治療のためのｋａｔ６阻害剤を含む投与レジメン |
| KR20250157556A (ko) * | 2023-03-27 | 2025-11-04 | 베이징 콘런스 파마슈티칼 컴퍼니 리미티드 | 설폰아미드 화합물, 이의 약학적 조성물과 응용 |
| KR20250164842A (ko) | 2023-03-30 | 2025-11-25 | 화이자 인코포레이티드 | Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법 |
| TW202446378A (zh) * | 2023-04-19 | 2024-12-01 | 香港商英矽智能科技知識產權有限公司 | 離胺酸乙醯基轉移酶6a(kat6a)抑制劑、其組合及其用途 |
| CN117448454B (zh) * | 2023-10-30 | 2025-09-30 | 赣南医科大学 | Kat6a在制备结直肠癌肝转移诊断试剂盒中的应用 |
| WO2025098417A1 (zh) * | 2023-11-08 | 2025-05-15 | 再和医药科技（苏州）有限公司 | 磺酰胺类化合物及其应用 |
| WO2025141469A1 (en) | 2023-12-26 | 2025-07-03 | Pfizer Inc. | Crystalline form of 2-methoxy-n-{4-methoxy-6-[(1h-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL218692B1 (pl) | 2002-01-22 | 2015-01-30 | Warner Lambert Co | Podstawiony 2-(pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-on oraz jego zastosowanie do leczenia zaburzenia lub stanu spowodowanego nieprawidłową proliferacją komórek |
| AU2004255934B2 (en) | 2003-07-11 | 2010-02-25 | Warner-Lambert Company Llc | Isethionate salt of a selective CDK4 inhibitor |
| EP2069344A2 (en) | 2006-09-08 | 2009-06-17 | Pfizer Products Inc. | Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
| NZ702244A (en) * | 2012-06-08 | 2017-06-30 | Hoffmann La Roche | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| EP3431475B1 (en) | 2013-02-21 | 2021-04-07 | Pfizer Inc | Solid forms of a selective cdk4/6 inhibitor |
| GB201510019D0 (en) * | 2015-06-09 | 2015-07-22 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| BR112018068512A2 (pt) * | 2016-03-15 | 2019-01-22 | Merrimack Pharmaceuticals Inc | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 |
| GB201713962D0 (en) | 2017-08-31 | 2017-10-18 | Ctxt Pty Ltd | Compounds |
| CA3098283C (en) | 2018-04-26 | 2023-05-23 | Pfizer Inc. | 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors |
| GB201810092D0 (en) | 2018-06-20 | 2018-08-08 | Ctxt Pty Ltd | Compounds |
| GB201810581D0 (en) | 2018-06-28 | 2018-08-15 | Ctxt Pty Ltd | Compounds |
| CN112867930B (zh) | 2018-09-10 | 2025-03-18 | 3M创新有限公司 | 包括局部放电传感器的电力电缆监测装置 |
| CN114072394A (zh) * | 2019-04-25 | 2022-02-18 | 拜耳股份公司 | 用于治疗癌症的酰基磺酰胺 |
| IL288802B2 (en) * | 2019-06-18 | 2025-08-01 | Pfizer | Benzisoxazole sulfonamide derivatives |
-
2021
- 2021-07-15 PT PT217495506T patent/PT4181920T/pt unknown
- 2021-07-15 MX MX2023000735A patent/MX2023000735A/es unknown
- 2021-07-15 CN CN202180062860.6A patent/CN116113407A/zh active Pending
- 2021-07-15 BR BR112023000687A patent/BR112023000687A2/pt unknown
- 2021-07-15 DK DK21749550.6T patent/DK4181920T3/da active
- 2021-07-15 WO PCT/EP2021/069787 patent/WO2022013369A1/en not_active Ceased
- 2021-07-15 CA CA3189410A patent/CA3189410A1/en active Pending
- 2021-07-15 TW TW110126025A patent/TW202216131A/zh unknown
- 2021-07-15 AU AU2021308406A patent/AU2021308406A1/en not_active Abandoned
- 2021-07-15 FI FIEP21749550.6T patent/FI4181920T3/fi active
- 2021-07-15 EP EP21749550.6A patent/EP4181920B1/en active Active
- 2021-07-15 KR KR1020237005334A patent/KR20230058614A/ko active Pending
- 2021-07-15 JP JP2021116806A patent/JP2022019654A/ja active Pending
- 2021-07-15 IL IL299871A patent/IL299871A/en unknown
- 2021-07-15 EP EP25201195.2A patent/EP4667055A2/en active Pending
-
2023
- 2023-01-19 ZA ZA2023/00875A patent/ZA202300875B/en unknown
-
2025
- 2025-01-13 AU AU2025200238A patent/AU2025200238A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230058614A (ko) | 2023-05-03 |
| DK4181920T3 (da) | 2025-09-29 |
| CA3189410A1 (en) | 2022-01-20 |
| ZA202300875B (en) | 2023-09-27 |
| EP4181920B1 (en) | 2025-09-10 |
| FI4181920T3 (fi) | 2025-11-20 |
| EP4181920A1 (en) | 2023-05-24 |
| JP2022019654A (ja) | 2022-01-27 |
| IL299871A (en) | 2023-03-01 |
| WO2022013369A1 (en) | 2022-01-20 |
| CN116113407A (zh) | 2023-05-12 |
| AU2025200238A1 (en) | 2025-01-30 |
| AU2021308406A1 (en) | 2023-02-23 |
| EP4667055A2 (en) | 2025-12-24 |
| TW202216131A (zh) | 2022-05-01 |
| BR112023000687A2 (pt) | 2023-02-07 |
| MX2023000735A (es) | 2023-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4181920T (pt) | Inibidor de kat6 e combinações para o tratamento do cancro da mama | |
| IL284324A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL284326A (en) | Aza-heterobicyclic MAT2A inhibitors and methods for use in the treatment of cancer | |
| IL288395A (en) | Mat2a tricyclic inhibitors and methods for use in cancer therapy | |
| IL277665A (en) | Heterocyclic inhibitors of MAT2A and methods of use for cancer therapy | |
| IL304275A (en) | Cancer treatment methods | |
| IL286350A (en) | Preparations and methods for the treatment of cancer | |
| IL288914A (en) | Preparations and methods for the treatment of cancer | |
| IL312680A (en) | Cancer treatment methods | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| IL287982A (en) | Preparations and methods for the treatment of cancer | |
| SG11202109336UA (en) | Methods and compositions for treating cancer | |
| IL316829A (en) | Menin-MLL inhibitors for cancer treatment | |
| IL286153A (en) | Methods and preparations for the treatment of cancer | |
| IL315800A (en) | Preparations and methods for the treatment of cancer | |
| IL309120A (en) | Methods and compositions for the treatment of cancer | |
| IL305780A (en) | Cancer treatment methods | |
| IL288178A (en) | Combined gmci and ddri treatment for cancer | |
| IL287538A (en) | Preparations and methods for the treatment of cancer | |
| IL312846A (en) | Methods and preparations for the treatment of cancer | |
| IL309071A (en) | Methods and compositions for the treatment of cancer | |
| EP4284519A4 (en) | METHODS FOR TREATING AND ALLEVIATING CANCER | |
| EP4281560A4 (en) | METHODS FOR THE TREATMENT AND Palliation of Cancer | |
| GB202101728D0 (en) | Compounds and their use treating cancer | |
| IL285036A (en) | Methods and preparations for the treatment of cancer |